Pinned Tweet
Our official Twitter account for information and updates from Jazz Pharmaceuticals is @JazzPharma.
23
Our Q3 2026 results reflect continued progress across our commercial and R&D portfolio as we advance innovation and deliver for patients. Explore our Q3 results: bit.ly/4sCFgjC
For U.S. media and investors: At #SNO2026, we will present new clinical and preclinical research, highlighting our commitment to scientific innovation for people with rare and aggressive brain tumors. Learn more: bit.ly/4A5E2jv
#News for U.S. media and investors: At #ESMO26, we’re presenting our Phase 3 data in first-line HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). Learn more here: bit.ly/4BCWz8C
We're pleased to announce the successful completion of our acquisition of Actio Biosciences, further strengthening our neuroscience portfolio and expanding our work in rare epilepsies. Learn more: bit.ly/4xp9Yxu
Today, we announced positive combination survival results from the Phase 3 HERIZON-GEA-01 trial investigating our first-line treatment for adults with HER2+ advanced gastroesophageal adenocarcinoma (GEA). Learn more: bit.ly/4cmRm9P
#News for U.S. media and investors: The U.S. FDA has approved our HER2-targeted therapy as part of two first-line treatment regimens for adults with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). Learn more: bit.ly/46ntmjm
We're pleased to announce a definitive agreement to acquire Actio Biosciences, adding to our #epilepsy portfolio and reinforcing our commitment to bringing meaningful treatments to people living with rare diseases. Subject to customary closing conditions. bit.ly/4wCElAt
Our Q2 2026 results reflect strong execution, continued momentum, and progress against our long-term growth strategy. Explore our Q2 results: bit.ly/4pREspI
418
We’re proud to share our 2025 Corporate Sustainability and Social Impact (CSSI) Report. It reflects how we’re advancing our purpose, delivering impact and building trust with key stakeholders. Read more: bit.ly/4b9oUYe
1
1
422
#News for U.S. media and investors: We’re pleased to announce a pre-clinical research collaboration and option-to-license agreement with @AbCelleraBio to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies for GI cancers: bit.ly/43KwDbk
#News for U.S. media and investors: At #SLEEP2026 we’re presenting 11 late-breaking data presentations, advancing understanding for rare sleep disorders. Learn more: bit.ly/4xtq4aV
We are excited to be on the ground at #SLEEP2026 this week, where we are connecting with fellow leaders in the sleep community, like @American_Heart, to share more on the critical connection between sleep, sodium intake and hypertension. Learn more below.
Stop by Booth 832 to learn more about how sleep and sodium intersect in managing hypertension and overall health. #SLEEP2026
🗓️ June 14-17
📍Baltimore Convention Center
Jazz Pharmaceuticals, Inc. is proud to support the American Heart Association’s Hypertension, Sodium and Sleep Professional Education Initiative.
Global Head of R&D and Chief Medical Officer Rob Iannone sat down with @FiercePharma to discuss the evolving HER2-targeted treatment landscape and Jazz’s strategic focus in HER2 to help address unmet needs for patients. Watch the full interview: bit.ly/4egsZuJ
2
267
#News for U.S. media and investors: We are proud to attend #SLEEP2026 and present research on rare sleep disorders. Learn more about our data: bit.ly/4ukzPFx
228
As we kick off #ASCO26, we’re excited to be presenting on Monday additional subgroup analyses from our Phase 3 trial in HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). Learn more about the results, recently published in @NEJM: bit.ly/4uCsOAU
We are joining the global cancer research community at #ASCO26 this weekend. With three rapid oral presentations and additional posters, we’re sharing data from across our oncology portfolio that reflect our ongoing efforts in some of the most difficult-to-treat cancers.
1
221
#News for U.S. media and investors: @NEJM has published our Phase 3 results for HER2+ gastroesophageal adenocarcinoma (GEA), representing potential hope for patients with this rare disease who have historically faced limited long-term options. Learn more: bit.ly/4uCsOAU
#News for U.S. media and investors: Jazz announces first quarter 2026 financial results $JAZZ: bit.ly/49v7VyN
338
#News for U.S. media and investors: Today, the U.S. FDA accepted and granted Priority Review for the supplemental Biologic License Application (sBLA) for our potential treatment for HER2+ unresectable locally advanced or metastatic GEA. Learn more: bit.ly/4sYvF5s


















